Pr. Marc AURIACOMBE

Publications



Articles

2021

  1. Auriacombe, M.; Fournet, L.; Dupuy, L.; Micoulaud-Franchi, J-A.; de Sevin, E.; Moriceau, S.; Baillet, E.; Alexandre, J-M.; Serre, F. and Philip, P. Effectiveness and Acceptance of a Smartphone-Based Virtual Agent Screening for Alcohol and Tobacco Problems and Associated Risk Factors During COVID-19 Pandemic in the General Population. In Frontiers in Psychiatry, 12, 2021. doi 
  2. Bahadoor, R.; Alexandre, J-M.; Fournet, L.; Gellé, T.; Serre, F. and Auriacombe, M. Inventory and Analysis of Controlled Trials of Mobile Phone Applications Targeting Substance Use Disorders: A Systematic Review. In Frontiers in Psychiatry, 12, 2021. doi 
  3. Dupuy, L.; De Sevin, E.; Bioulac, S.; Taillard, J.; Salles, N.; Serre, F.; Auriacombe, M.; Micoulaud-Franchi, J-a. and Philip, P. Efficacité d'une TCC contre l'insomnie dispensée par un agent virtuel : Résultats pendant et après le confinement du COVID-19. In Médecine du Sommeil, 18 (1): 26, 2021. doi 
  4. Dupuy, L.; Morin, C. M.; Sevin, E.; Taillard, J.; Salles, N.; Bioulac, S.; Auriacombe, M.; Micoulaud‐Franchi, J. and Philip, P. Smartphone‐based virtual agents and insomnia management: A proof‐of‐concept study for new methods of autonomous screening and management of insomnia symptoms in the general population. In Journal of Sleep Research, 2021. doi 
  5. Dupuy, M.; Abdallah, M.; Swendsen, J.; N'Kaoua, B.; Chanraud, S.; Schweitzer, P.; Fatseas, M.; Serre, F.; Barse, E.; Auriacombe, M. and Misdrahi, D. Real-time cognitive performance and positive symptom expression in schizophrenia. In European Archives of Psychiatry and Clinical Neuroscience, 2021. doi 
  6. Fonseca, F.; Lenahan, W.; Dart, R. C.; Papaseit, E.; Dargan, P. I.; Wood, D. M.; Guareschi, M.; Maremmani, I.; Auriacombe, M.; Farré, M.; Scherbaum, N. and Torrens, M. Non-medical Use of Prescription Gabapentinoids (Gabapentin and Pregabalin) in Five European Countries. In Frontiers in Psychiatry, 12, 2021. doi 
  7. Grall-Bronnec, M.; Guillou-Landreat, M.; Caillon, J.; Dubertret, C.; Romo, L.; Codina, I.; Chereau-Boudet, I.; Lancon, C.; Auriacombe, M.; _, _; Hardouin, J-B. and Challet-Bouju, G. Five-year follow-up on a sample of gamblers: predictive factors of relapse. In Journal of Behavioral Addictions, 10 (1): 42-54, 2021. doi 
  8. Loyal, D.; Sutter, A-L.; Auriacombe, M.; Serre, F.; Calcagni, N. and Rascle, N. Stigma Attached to Smoking Pregnant Women: A Qualitative Insight in the General French Population. In Nicotine & Tobacco Research, 2021. doi 
  9. Maremmani, I.; Hill, D.; Scherbaum, N.; Auriacombe, M.; Bacciardi, S.; Benyamina, A.; Casella, P.; D'agnone, O.; Daulouede, J. P.; Deruvo, G.; Fonseca, F.; Guareschi, M. et al. Early-readmission after agonist opioid treatment in five european countriea drug addiction health policy challenge?. In Heroin Addiction and Related Clinical Problems, 23 (4), 2021.
  10. Philip, P.; Dupuy, L.; Morin, C.; De Sevin, &.; Bioulac, S.; Taillard, J.; Serre, F.; Auriacombe, M. and Micoulaud-Franchi, J-A. Des agents virtuels sur smartphone pour faire face aux plaintes de sommeil pendant le confinement du COVID-19 : étude de faisabilité. In Médecine du Sommeil, 18 (1): 43, 2021. doi 
  11. Ternon, A.; Dubernet, J.; Jakubiec, L.; Alexandre, J. M. and Auriacombe, M. Usage de protoxyde d'azote au sein d'une population d'étudiants en médecine. État des lieux de la consommation. Recherche de facteurs associés à cette consommation : stress lié au travail et usage problématique d'autres substances. In Therapies, 76 (2): 175, 2021. doi 

2020

  1. Kervran, C.; Shmulewitz, D.; Serre, F.; Stohl, M.; Denis, C.; Hasin, D. and Auriacombe, M. Item Response Theory analyses of DSM-5 substance use disorder criteria in French outpatient addiction clinic participants. How much is craving special?. In Drug and Alcohol Dependence, 212: 108036, 2020. doi 
  2. Kinouani, S.; Leflot, C.; Vanderkam, P.; Auriacombe, M.; Langlois, E. and Tzourio, C. Motivations for using electronic cigarettes in young adults: A systematic review. In Substance Abuse, 41 (3): 315-322, 2020. doi 
  3. Philip, P.; Dupuy, L.; Auriacombe, M.; Serre, F.; de Sevin, E.; Sauteraud, A. and Micoulaud-Franchi, J-A. Trust and acceptance of a virtual psychiatric interview between embodied conversational agents and outpatients. In npj Digital Medicine, 3 (1): 2, 2020. doi 
  4. Philip, P.; Dupuy, L.; Morin, C. M.; de Sevin, E.; Bioulac, S.; Taillard, J.; Serre, F.; Auriacombe, M. and Micoulaud-Franchi, J-A. Smartphone-Based Virtual Agents Can Help the General Population Concerned by Sleep Complaints: A Proof-of-Concept Study During COVID-19 Confinement. In SSRN Electronic Journal, 2020. doi 
  5. Philip, P.; Dupuy, L.; Morin, C. M.; de Sevin, E.; Bioulac, S.; Taillard, J.; Serre, F.; Auriacombe, M. and Micoulaud-Franchi, J-A. Smartphone-Based Virtual Agents to Help Individuals With Sleep Concerns During COVID-19 Confinement: Feasibility Study. In Journal of Medical Internet Research, 22 (12): e24268, 2020. doi 

2019

  1. Auriacombe, M.; Roux, P.; Briand Madrid, L.; Kirchherr, S.; Kervran, C.; Chauvin, C.; Gutowski, M.; Denis, C.; Carrieri, M. P.; Lalanne, L. and Jauffret-Roustide, M. Impact of drug consumption rooms on risk practices and access to care in people who inject drugs in France: the COSINUS prospective cohort study protocol. In BMJ Open, 9 (2): e023683, 2019. doi 
  2. Benchebra, L.; Alexandre, J-M.; Dubernet, J.; Fatséas, M. and Auriacombe, M. Addiction aux jeux (d'argent et vidéo) et état de santé des joueurs : une revue critique de la littérature. In La Presse Médicale, 48 (12): 1551-1568, 2019. doi 
  3. Kaye, S.; Ramos-Quiroga, J. A.; van de Glind, G.; Levin, F. R; Faraone, S. V; Allsop, S.; Degenhardt, L.; Moggi, F.; Barta, C.; Konstenius, M.; Franck, J.; Skutle, A. et al. Persistence and Subtype Stability of ADHD Among Substance Use Disorder Treatment Seekers. In Journal of Attention Disorders, 23 (12): 1438-1453, 2019. doi 
  4. Leouzon, H.; Alexandre, J-M.; Fatséas, M. and Auriacombe, M. L'addiction aux jeux vidéo dans le DSM-5, controverses et réponses relatives à son diagnostic et sa définition. In Annales Médico-psychologiques, revue psychiatrique, 177 (7): 610-623, 2019. doi 
  5. Micoulaud-Franchi, J-A.; Dupuy, L.; Moriceau, S.; Auriacombe, M. and Philip, P. 0922 Embodied Conversational Agents Are Highly Accepted to Diagnose Psychiatric Disorders among Patients Suffering from Sleep Disorders. In Sleep, 42 (Supplement_1): A370-A371, 2019. doi 

2018

  1. Auriacombe, M.; Fatséas, M.; Daulouède, J-P. and Tignol, J. Le craving et nouvelle clinique de l'addiction : une perspective simplifiée et opérationnelle. In Annales Médico-psychologiques, revue psychiatrique, 176 (8): 746-749, 2018. doi 
  2. Auriacombe, M.; Moriceau, S.; Serre, F.; Denis, C.; Micoulaud-Franchi, J-A.; de Sevin, E.; Bonhomme, E.; Bioulac, S.; Fatseas, M. and Philip, P. Development and validation of a virtual agent to screen tobacco and alcohol use disorders. In Drug and Alcohol Dependence, 193: 1-6, 2018. doi 
  3. Bouvard, A.; Dupuy, M.; Schweitzer, P.; Revranche, M.; Fatseas, M.; Serre, F.; Misdrahi, D.; Auriacombe, M. and Swendsen, J. Feasibility and validity of mobile cognitive testing in patients with substance use disorders and healthy controls. In The American Journal on Addictions, 27 (7): 553-556, 2018. doi 
  4. Dupouy, J.; Vergnes, A.; Laporte, C.; Kinouani, S.; Auriacombe, M.; Oustric, S. and Rougé Bugat, M-E. Intensity of previous teaching but not diagnostic skills influences stigmatization of patients with substance use disorder by general practice residents. A vignette study among French final-year residents in general practice. In European Journal of General Practice, 24 (1): 160-166, 2018. doi 
  5. Dupuy, M.; Misdrahi, D.; N'Kaoua, B.; Tessier, A.; Bouvard, A.; Schweitzer, P.; Auriacombe, M.; Serre, F.; Fatseas, M. and Swendsen, J. Mobile cognitive testing in patients with schizophrenia: A controlled study of feasibility and validity. In Journal de Thérapie Comportementale et Cognitive, 28 (4): 204-213, 2018. doi 
  6. Fatseas, M.; Serre, F.; Swendsen, J. and Auriacombe, M. Effects of anxiety and mood disorders on craving and substance use among patients with substance use disorder: An ecological momentary assessment study. In Drug and Alcohol Dependence, 187: 242-248, 2018. doi 
  7. Lemasson, M.; Rochette, L.; Galvão, F.; Poulet, E.; Lacroix, A.; Lecompte, M.; Auriacombe, M.; Patry, S. and Haesebaert, F. Pertinence of Titration and Age-Based Dosing Methods for Electroconvulsive Therapy. In The Journal of ECT, 34 (4): 220-226, 2018. doi 
  8. Serre, F.; Fatseas, M.; Denis, C.; Swendsen, J. and Auriacombe, M. Predictors of craving and substance use among patients with alcohol, tobacco, cannabis or opiate addictions: Commonalities and specificities across substances. In Addictive Behaviors, 83: 123-129, 2018. doi 

2017

  1. Auriacombe, M.; Alexandre, J-M.; Dubernet, J.; Tanguy, J. and Fatseas, M. Contribution of e-learning to addiction teaching: A successful experience at the university of bordeaux, France. In Drug and Alcohol Dependence, 171: e12, 2017. doi 
  2. Dematteis, M.; Auriacombe, M.; D'Agnone, O.; Somaini, L.; Szerman, N.; Littlewood, R.; Alam, F.; Alho, H.; Benyamina, A.; Bobes, J.; Daulouede, J. P.; Leonardi, C. et al. Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. In Expert Opinion on Pharmacotherapy, 18 (18): 1987-1999, 2017. doi 
  3. Denis, C. M.; da Rosa, M. A. C.; Serre, F.; Kervran, C.; Henry, M.; Cherifi, B.; Auriacombe, M. and Fatseas, M. Are DSM-5 criteria for sud transferable to food addiction? IRT analysis for alcohol, tobacco, cannabis, opiate and food addiction in a clinical sample. In Drug and Alcohol Dependence, 171: e52, 2017. doi 
  4. Dupouy, J.; Palmaro, A.; Fatséas, M.; Auriacombe, M.; Micallef, J.; Oustric, S. and Lapeyre-Mestre, M. Mortalité associée aux périodes sous et hors traitement par buprénorphine. In Therapies, 72 (1): 164, 2017. doi 
  5. Dupouy, J.; Palmaro, A.; Fatséas, M.; Auriacombe, M.; Micallef, J.; Oustric, S. and Lapeyre-Mestre, M. Mortality Associated With Time in and Out of Buprenorphine Treatment in French Office-Based General Practice: A 7-Year Cohort Study. In The Annals of Family Medicine, 15 (4): 355-358, 2017. doi 
  6. Fatseas, M.; Henry, M.; da Rosa, M. A. C.; Collombat, J.; Gregoire, A.; Kervran, C.; Cherifi, B. and Auriacombe, M. Eating disorder, food addiction and associated factors in obese patients. In Drug and Alcohol Dependence, 171: e62, 2017. doi 
  7. Rolland, B; Bouhassira, D; Authier, N; Auriacombe, M; Martinez, V; Polomeni, P; Brousse, G; Schwan, R; Lack, P; Bachellier, J; Rostaing, S; Bendimerad, P et al. Mésusage et dépendance aux opioïdes de prescription : prévention, repérage et prise en charge. In La Revue de Médecine Interne, 38 (8): 539-546, 2017. doi 
  8. Serre, F.; Fatseas, M.; Swendsen, J. and Auriacombe, M. How psychiatric comorbidity and mood states influence craving and substance use in daily life? An ecological momentary assessment study in patients with alcohol, tobacco, cannabis and heroin use disorders. In Drug and Alcohol Dependence, 171: e187, 2017. doi 
  9. Techer, L.; Alexandre, J-M.; Mété, D.; Auriacombe, M. and Fatseas, M. Addictive behaviors and psychiatric comorbidities of incarcerated women in a French overseas territory. In Drug and Alcohol Dependence, 171: e201, 2017. doi 

2016

  1. Auriacombe, M; Debrabant, R; Kervran, C; Serre, F; Taillard, J; Philip, P; Denis, C and Fatséas, M Addiction et troubles du sommeil : craving, rythmes circadiens. Une mise au point. In Médecine du Sommeil, 13 (3): 91-99, 2016. doi 
  2. Denis, C.; Fatséas, M.; Beltran, V.; Serre, F.; Alexandre, J-M.; Debrabant, R.; Daulouède, J-P. and Auriacombe, M. Usefulness and validity of the modified Addiction Severity Index: A focus on alcohol, drugs, tobacco, and gambling. In Substance Abuse, 37 (1): 168-175, 2016. doi 
  3. Fatséas, M.; Hurmic, H.; Serre, F.; Debrabant, R.; Daulouède, J-P.; Denis, C. and Auriacombe, M. Addiction severity pattern associated with adult and childhood Attention Deficit Hyperactivity Disorder (ADHD) in patients with addictions. In Psychiatry Research, 246: 656-662, 2016. doi 
  4. Fatseas, M.; Kervran, C. and Auriacombe, M. Troubles du sommeil et addictions : impact sur la qualité de vie et le risque de rechute. In La Presse Médicale, 45 (12): 1164-1169, 2016. doi 
  5. Petry, N. M; Rehbein, F.; Gentile, D. A; Lemmens, J. S; Rumpf, H-J.; Mössle, T.; Bischof, G.; Tao, R.; Fung, D. S S; Borges, G.; Auriacombe, M.; González‐Ibáñez, A. et al. Griffiths et al .'s comments on the international consensus statement of internet gaming disorder: furthering consensus or hindering progress?. In Addiction, 111 (1): 175-178, 2016. doi 
  6. Werb, D.; Garfein, R.; Kerr, T.; Davidson, P.; Roux, P.; Jauffret-Roustide, M.; Auriacombe, M.; Small, W. and Strathdee, S. A A socio-structural approach to preventing injection drug use initiation: rationale for the PRIMER study. In Harm Reduction Journal, 13 (1): 25, 2016. doi 

2015

  1. Alexandre, J-M.; Fatseas, M.; Bouju, G.; Legauffre, C.; Valleur, M.; Magalon, D.; Chereau-Boudet, I.; Gorsane, M.; Auriacombe, M.; Hardouin, J.; Venisse, J. and Grall-Bronnec, M. Gambling behavior among gamblers with and without attention deficit/hyperactivity disorder. In Drug and Alcohol Dependence, 146: e205-e206, 2015. doi 
  2. Auriacombe, M.; Denis, C. M.; Rosa, M. A. C.; Collombat, J.; Serre, F.; Daulouede, J-P. and Fatseas, M. Validity of the eating section for the modified addiction severity index. In Drug and Alcohol Dependence, 156: e12, 2015. doi 
  3. Daulouède, J-P.; Denis, C. M.; Fatseas, M.; Beltran, V. and Auriacombe, M. Risk-taking behavior over 36-month follow-up treatment in outpatient opioid maintenance treatment program. In Drug and Alcohol Dependence, 146: e258, 2015. doi 
  4. Denis, C. M.; Fatseas, M.; Beltran, V.; Daulouede, J-P. and Auriacombe, M. Impact of 20 years harm reduction policy on HIV and HCV among opioid users not in treatment. In Drug and Alcohol Dependence, 146: e261, 2015. doi 
  5. Denis, C. M.; Metzger, D.; Huang, L.; Trias, V.; Auriacombe, M.; Raguin, G.; Hoai, S. M. T.; Le Truong, G.; Daulouede, J-P. and O'Brien, C. P. A 6-month follow-up of the integrated treatment for opiate addiction and HIV in Vietnam. In Drug and Alcohol Dependence, 156: e56-e57, 2015. doi 
  6. Duburque, C.; Canva, V.; Auriacombe, M.; Djomboue, P.; Hernout, B.; Lucidarme, D. and Harbonnier, J. A 3 year follow-up of HCV infection in opioid use disorder patients in treatment. In Drug and Alcohol Dependence, 156: e60, 2015. doi 
  7. Fatseas, M.; Collombat, J.; Rosa, M. A. C.; Denis, C. M.; Alexandre, J-M.; Debrabant, R.; Serre, F. and Auriacombe, M. Measuring “craving” in food addiction: Type, frequency, intensity. In Drug and Alcohol Dependence, 156: e66, 2015. doi 
  8. Fatseas, M; Hurmic, H.; Debrabant, R.; Serre, F and Auriacombe, M. Substance use patterns associated with adult ADHD in SUD treatment-seeking patients: Results from the aquitaine addiction cohort study. In Drug and Alcohol Dependence, 146: e274-e275, 2015. doi 
  9. Fatseas, M.; Serre, F.; Alexandre, J-M.; Debrabant, R.; Auriacombe, M. and Swendsen, J. Craving and substance use among patients with alcohol, tobacco, cannabis or heroin addiction: a comparison of substance- and person-specific cues. In Addiction, 110 (6): 1035-1042, 2015. doi 
  10. Hurmic, H.; Debrabant, R.; Kervran, C.; Serre, F.; Auriacombe, M. and Fatseas, M. ADHD and substance use disorders: Subtype and gender differences. In Drug and Alcohol Dependence, 156: e100-e101, 2015. doi 
  11. Hurmic, H.; Debrabant, R.; Serre, F.; Fatseas, M.; Alix, M. and Auriacombe, M. Frequency and intensity of craving among addicted patients during outpatient treatment. In Drug and Alcohol Dependence, 146: e145, 2015. doi 
  12. Kervran, C.; Debrabant, R.; Taillard, J.; Philip, P.; Auriacombe, M. and Fatseas, M. Association between morningness/eveningness, addiction severity and psychiatric disorders among individuals with addictions. In Drug and Alcohol Dependence, 156: e108, 2015. doi 
  13. Kervran, C; Serre, F; Fatseas, M; Debrabant, R.; Trouba, C; Taillard, J; Philip, P and Auriacombe, M. Sleep quality in patients with SUD and behavioral addictions assessed by actigraphy: A prospective study. In Drug and Alcohol Dependence, 146: e156-e157, 2015. doi 
  14. Kervran, C.; Fatséas, M.; Serre, F.; Taillard, J.; Beltran, V.; Leboucher, J.; Debrabant, R.; Alexandre, J-M.; Daulouède, J-P.; Philip, P. and Auriacombe, M. Association between morningness/eveningness, addiction severity and psychiatric disorders among individuals with addictions. In Psychiatry Research, 229 (3): 1024-1030, 2015. doi 
  15. Lhommeau, N.; Alexandre, J-M.; Mete, D.; Fatseas, M. and Auriacombe, M. Characteristics of gamblers choosing self-exclusion from casinos: A prospective study in a French overseas territory. In Drug and Alcohol Dependence, 156: e127, 2015. doi 
  16. Rosa, M. A. C.; Collombat, J.; Denis, C. M.; Alexandre, J-M.; Serre, F.; Auriacombe, M. and Fatseas, M. Overlap between food addiction and DSM-5 eating disorders in a treatment seeking sample. In Drug and Alcohol Dependence, 156: e192, 2015. doi 
  17. Serre, F.; Fatseas, M.; Swendsen, J. and Auriacombe, M. Does craving intensity influence cue exposure reports? An ecological momentary assessment study in patients with alcohol, tobacco, cannabis and heroin use disorder. In Drug and Alcohol Dependence, 156: e201, 2015. doi 
  18. Serre, F.; Fatseas, M.; Swendsen, J. and Auriacombe, M. Corrigendum to “Ecological momentary assessment in the investigation of craving and substance use in daily life: A systematic review” Drug and Alcohol Dependence 148 (2015) 1–20. In Drug and Alcohol Dependence, 154: 305-314, 2015. doi 
  19. Serre, F.; Fatseas, M.; Swendsen, J. and Auriacombe, M. Ecological momentary assessment in the investigation of craving and substance use in daily life: A systematic review. In Drug and Alcohol Dependence, 148: 1-20, 2015. doi 
  20. Skutle, A.; Bu, E. T. H.; Jellestad, F. K.; van Emmerik-van Oortmerssen, K.; Dom, G.; Verspreet, S.; Carpentier, P. J.; Ramos-Quiroga, J. A.; Franck, J.; Konstenius, M.; Kaye, S.; Demetrovics, Z. et al. Early developmental, temperamental and educational problems in ‘substance use disorder' patients with and without ADHD. Does ADHD make a difference?. In Addictive Behaviors Reports, 2: 13-18, 2015. doi 
  21. Wapp, M.; van de Glind, G.; van Emmerik-van Oortmerssen, K.; Dom, G.; Verspreet, S.; Carpentier, P. J.; Ramos-Quiroga, J. A.; Skutle, A.; Bu, E-T.; Franck, J.; Konstenius, M.; Kaye, S. et al. Risk Factors for Borderline Personality Disorder in Treatment Seeking Patients with a Substance Use Disorder: An International Multicenter Study. In European Addiction Research, 21 (4): 188-194, 2015. doi 

2014

  1. Auriacombe, M; Denis, C and Fatseas, M Commentary on Sharkow et al. (2014): Longitudinal patterns of problematic computer game use among adolescents and adults – a 2-year panel study. Welcomed and yet to come. Are we looking at what we are looking for?. In Addiciton, 2014.
  2. Auriacombe, M.; Denis, C. M.; Beltran, V.; Alexandre, J.; Debrabant, R.; Serre, F.; Daulouede, J-P. and Fatseas, M. 10-years outcome of methadone- and buprenorphine-maintained patients. Mortality, quality of life and substance use. In Drug and Alcohol Dependence, 140: e8, 2014. doi 
  3. Denis, C. M.; Fleury, B.; Nalpas, B.; Crapelet, M. and Auriacombe, M. Correlation between severity of addiction and level of services received by alcohol use disorder outpatients in France. In Drug and Alcohol Dependence, 140: e48, 2014. doi 
  4. Fatseas, F; Debrabant, R and Auriacombe, M Usage de substances psychoactives et TDA/H. In Aide Mémoire des TDA/H à tous les âges, 2014.
  5. Fleury, B.; Denis, C. M.; Nalpas, B.; Crapelet, M. and Auriacombe, M. Patient motivation and 12-month treatment outcome in alcohol use disorder outpatients in France. In Drug and Alcohol Dependence, 140: e61, 2014. doi 
  6. Gazel, C; Fatseas, M and Auriacombe, M Quels changements pour les addictions dans le DSM 5 ?. In La Lettre du Psychiatre, 10 (2): 50-53, 2014.
  7. Lofwall, M. R; Martin, J.; Tierney, M.; Fatséas, M.; Auriacombe, M. and Lintzeris, N. Buprenorphine Diversion and Misuse in Outpatient Practice. In Journal of Addiction Medicine, 8 (5): 327-332, 2014. doi 
  8. Petry, N. M; Blanco, C.; Auriacombe, M.; Borges, G.; Bucholz, K.; Crowley, T. J; Grant, B. F; Hasin, D. S and O'Brien, C. An Overview of and Rationale for Changes Proposed for Pathological Gambling in DSM-5. In Journal of Gambling Studies, 30 (2): 493-502, 2014. doi 
  9. Petry, N. M; Rehbein, F.; Gentile, D. A; Lemmens, J. S; Rumpf, H-J.; Mössle, T.; Bischof, G.; Tao, R.; Fung, D. S. S.; Borges, G.; Auriacombe, M.; González Ibáñez, A. et al. An international consensus for assessing internet gaming disorder using the new DSM-5 approach. In Addiction, 109 (9): 1399-1406, 2014. doi 
  10. Petry, N. M; Rehbein, F.; Gentile, D. A; Lemmens, J. S; Rumpf, H-J.; Mössle, T.; Bischof, G.; Tao, R.; Fung, D. S. S.; Borges, G.; Auriacombe, M.; GonzálezIbáñez, A. et al. Moving internet gaming disorder forward: A reply. In Addiction, 109 (9): 1412-1413, 2014. doi 
  11. Petry, N. M; Rehbein, F.; Gentile, D. A; Lemmens, J. S; Rumpf, H-J.; Mössle, T.; Bischof, G.; Tao, R.; Fung, D. S. S.; Borges, G.; Auriacombe, M.; GonzálezIbáñez, A. et al. Internet gaming and addiction: a reply to King & Delfabbro. In Addiction, 109 (9): 1567-1568, 2014. doi 
  12. Serre, F.; Fatseas, M.; Swendsen, J. and Auriacombe, M. Does craving predict substance use for different substance use disorders? An ecological momentary assessment study in patients with alcohol, tobacco, cannabis and heroin dependence. In Drug and Alcohol Dependence, 140: e202-e203, 2014. doi 
  13. Serre, F; Fatseas, M; Swendsen, J and Auriacombe, M Are sleep disturbances associated with craving intensity?: What is the influence of psychiatric comorbidity and type of substance on this relationship? A computerized ambulatory monitoring study in patients beginning treatment for addiction. In 76th College on Problems of Drug Dependence, 2014.
  14. Serre, F; Fatséas, M; Swendsen, J; Taillard, J; Philip, P and Auriacombe, M Relation entre problèmes de sommeil et envie de consommer (craving) chez des sujets dépendants en début de prise en charge pour leur addiction. In Medecine du sommeil, 11 (34), 2014.
  15. van de Glind, G.; Konstenius, M.; Koeter, M. W.J.; van Emmerik-van Oortmerssen, K.; Carpentier, P-J.; Kaye, S.; Degenhardt, L.; Skutle, A.; Franck, J.; Bu, E-T.; Moggi, F.; Dom, G. et al. Variability in the prevalence of adult ADHD in treatment seeking substance use disorder patients: Results from an international multi-center study exploring DSM-IV and DSM-5 criteria. In Drug and Alcohol Dependence, 134 (1): 158-166, 2014. doi 
  16. van Emmerik-van Oortmerssen, K.; van de Glind, G.; Koeter, M. W J; Allsop, S.; Auriacombe, M.; Barta, C.; Bu, E. T. H; Burren, Y.; Carpentier, P-J.; Carruthers, S.; Casas, M.; Demetrovics, Z. et al. Psychiatric comorbidity in treatment-seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study. In Addiction, 109 (2): 262-272, 2014. doi 

2013

  1. Alexandre, J M; Fatséas, M; Dubernet, J; Tanguy, J and Auriacombe, M Apports du e-learning à la formation clinique. In Santé Mentale (175): 14-17, 2013.
  2. Alho, H; Auriacombe, M; Fischer, G; Maremmani, I; Scherbaum, N and Torrens, M Can outcomes monitoring of opioid maintenance treatment be improved in Europe?: A statement by some European experts with interests in opioid maintenance treatment and its safety. In Heroin Addiction And Related Clinical Problems, 15 (1): 63-64, 2013.
  3. Fatseas, M; Denis, C; Debrabant, R; Mathillon, V; Beltran, V; Daulouède, J P; Balducci, M and Auriacombe, M Changes in Sleep Quality in Opiate-Dependent Subjects in Methadone and Buprenorphine Maintenance Treatment over a 12-month period. In Heroin Addiction and Related Clinical Problems, 15 (1): 39-44, 2013.
  4. Hasin, D. S; Auriacombe, M.; Borges, G.; Bucholz, K.; Budney, A.; Crowley, T.; Grant, B. F; O'Brien, C.; Petry, N. M; Schuckit, M. and Wall, M. M The DSM-5 Field Trials and Reliability of Alcohol Use Disorder. In American Journal of Psychiatry, 170 (4): 442-443, 2013. doi 
  5. Hasin, D. S; O'Brien, C. P.; Auriacombe, M.; Borges, G.; Bucholz, K.; Budney, A.; Compton, W. M; Crowley, T.; Ling, W.; Petry, N. M; Schuckit, M. and Grant, B. F DSM-5 Criteria for Substance Use Disorders: Recommendations and Rationale. In American Journal of Psychiatry, 170 (8): 834-851, 2013. doi 
  6. Sarram, S; Debrabant, R; Fatseas, M; Daulouede, J P; Sagaspe, P; Taillard, J; Philip, P and Auriacombe, M Changes in sleep quality and alertness in opiate-dependent subjects after stable methadone and buprenorphine maintenance treatment. A pilot exploratory report. In Heroin Addiction and Related Clinical Problems, 15 (1): 39-44, 2013.
  7. van de Glind, G.; van den Brink, W.; Koeter, M. W.J.; Carpentier, P-J.; van Emmerik-van Oortmerssen, K.; Kaye, S.; Skutle, A.; Bu, E-T. H.; Franck, J.; Konstenius, M.; Moggi, F.; Dom, G. et al. Validity of the Adult ADHD Self-Report Scale (ASRS) as a screener for adult ADHD in treatment seeking substance use disorder patients. In Drug and Alcohol Dependence, 132 (3): 587-596, 2013. doi 

2012

  1. Alexandre, J-M.; Fatseas, M and Auriacombe, M Addiction(s)?. In Biofutur, 338: 27-29, 2012.
  2. Bosc, E; Fatséas, M.; Alexandre, J.-M. and Auriacombe, M Similitudes et différences entre le jeu pathologique et la dépendance aux substances : qu'en est-il ?. In L'Encéphale, 38 (5): 433-439, 2012. doi 
  3. Denis, C.; Fatséas, M. and Auriacombe, M. Analyses related to the development of DSM-5 criteria for substance use related disorders: 3. An assessment of Pathological Gambling criteria. In Drug and Alcohol Dependence, 122 (1-2): 22-27, 2012. doi 
  4. Denis, C.; Fatséas, M.; Beltran, V.; Bonnet, C.; Picard, S.; Combourieu, I.; Daulouède, J-P. and Auriacombe, M. Validity of the Self-Reported Drug Use Section of the Addiction Severity Index and Associated Factors Used under Naturalistic Conditions. In Substance Use & Misuse, 47 (4): 356-363, 2012. doi 
  5. Fatseas, M.; Debrabant, R. and Auriacombe, M. The diagnostic accuracy of attention-deficit/hyperactivity disorder in adults with substance use disorders. In Current Opinion in Psychiatry, 25 (3): 219-225, 2012. doi 
  6. Fatseas, M.; Denis, C.; Serre, F.; Dubernet, J.; Daulouède, J-P. and Auriacombe, M. Change in HIV-HCV Risk-Taking Behavior and Seroprevalence Among Opiate Users Seeking Treatment Over an 11-year Period and Harm Reduction Policy. In AIDS and Behavior, 16 (7): 2082-2090, 2012. doi 
  7. Gense de Beaufort, D.; Sesay, M; Stinus, L; Thiebaut, R; Auriacombe, M and Dousset, V Cerebral blood flow modulation by transcutaneous cranial electrical stimulation with Limoge's current. In Journal of Neuroradiology, 39 (3): 167-175, 2012. doi 
  8. Malivert, M.; Fatséas, M.; Denis, C.; Langlois, E. and Auriacombe, M. Effectiveness of Therapeutic Communities: A Systematic Review. In European Addiction Research, 18 (1): 1-11, 2012. doi 
  9. Serre, F; Denis, C; Fatseas, M and Auriacombe, M Santé, travail et addiction. In Le Courrier des Addictions, 14: 22-23, 2012.
  10. Serre, F.; Fatseas, M.; Debrabant, R.; Alexandre, J-M.; Auriacombe, M. and Swendsen, J. Ecological momentary assessment in alcohol, tobacco, cannabis and opiate dependence: A comparison of feasibility and validity. In Drug and Alcohol Dependence, 126 (1-2): 118-123, 2012. doi 

2011

  1. Auriacombe, M Conseil pour un fumeur et son entourage non-fumeur. In Le Courrier des Addictions: 13:16, 2011.
  2. Denis, C.; Langlois, E.; Fatséas, M.; Auriacombe, M. and Auriacombe, Pr. M. Un modèle français de Communauté Thérapeutique ? Les communautés thérapeutiques expérimentales : Consensus des professionnels. In Psychotropes, 17 (3): 85, 2011. doi 
  3. Fatseas, M.; Denis, C.; Massida, Z.; Verger, M.; Franques-Rénéric, P. and Auriacombe, M. Cue-Induced Reactivity, Cortisol Response and Substance Use Outcome in Treated Heroin Dependent Individuals. In Biological Psychiatry, 70 (8): 720-727, 2011. doi 

2010

  1. Alexandre, J-M.; Humeau, M; Fatseas, M and Auriacombe, M. E-learning : méthode efficace pour la formation continue. In Courrier des Addictions, 12: 23-24, 2010.
  2. Fatséas, M.; Denis, C.; Lavie, E. and Auriacombe, M. Relationship between anxiety disorders and opiate dependence— A systematic review of the literature. In Journal of Substance Abuse Treatment, 38 (3): 220-230, 2010. doi 
  3. MAITRE, C.; HERRAN, E.; RENAUDIN, J.; BECKER, I.; BELTRAN, V.; AURIACOMBE, M. and DAULOUEDE, J-P. Délivrance de la méthadone et de la buprénorphine: les pharmaciens du Pays Basque et du sud des Landes mènent l'enquête. In Le Courrier des addictions, 12 (4), 2010.

2009

  1. Alvarez, C. V.; Claros, J. a V.; Barkley, R. A; Huss, M.; Hölling, H.; Kurth, B. M.; Schlack, R.; López, I.; Rodillo, E.; Kleinsteuber, K.; eña,; ontiel-Nava, et al. Childhood predictors of adult ADHD: Results from the WHO World Mental Health (WMH) Survey Initiative. In Biol Psychiatry, 65 (1), 2009.
  2. Fatséas, M.; Lavie, E.; Denis, C. and Auriacombe, M. Self-perceived motivation for benzodiazepine use and behavior related to benzodiazepine use among opiate-dependent patients. In Journal of Substance Abuse Treatment, 37 (4): 407-411, 2009. doi 
  3. Lavie, E.; Fatséas, M.; Denis, C. and Auriacombe, M. Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: Correlates of use, abuse and dependence. In Drug and Alcohol Dependence, 99 (1-3): 338-344, 2009. doi 
  4. Le Bec, P.-Y.; Fatséas, M.; Denis, C; Lavie, E and Auriacombe, M Cannabis et psychose : recherche d'un lien de causalité à partir d'une revue critique systématique de la littérature. In L'Encéphale, 35 (4): 377-385, 2009. doi 

2008

  1. Lavie, E; Fatseas, M; Daulouede, J P; Denis, C; Dubernet, J; Cattan, L and Auriacombe, M Comparison of prescriber evaluations and patient-directed self-reports in office-based practice for buprenorphine treatment of opiate-dependent individuals in France, 2002. In Patient Preference and Adherence, 2: 369-378, 2008.
  2. Mazère, J.; Prunier, C; Barret, O; Guyot, M; Hommet, C; Guilloteau, D; Dartigues, J.F.; Auriacombe, S; Fabrigoule, C and Allard, M In vivo SPECT imaging of vesicular acetylcholine transporter using [123I]-IBVM in early Alzheimer's disease. In NeuroImage, 40 (1): 280-288, 2008. doi 
  3. Millet, X.; Le Goff, M.; Auriacombe, S.; Fabrigoule, C.; Dartigues, J-F. and Amieva, H. Exploring different routes of recovery from memory in Alzheimer's disease: Evidence for preserved long-term priming. In Journal of Clinical and Experimental Neuropsychology, 30 (7): 828-835, 2008. doi 

2007

  1. Fatseas, M and Auriacombe, M. Why buprenorphine is so successful in treating opiate addiction in France. In Current Psychiatry Reports, 9 (5): 358-364, 2007. doi 
  2. Schmid, R.; Fischer, G.; Mehic-Basara, N.; Kantchelov, A.; Ivancic, A.; Touzeau, D.; Auriacombe, M.; Krausz, M.; Quigley, P.; Pacini, M.; Pani, P. P.; Arieli, M. et al. eroin ddiction and elated linical roblems EUROPEAN OPIATE ADDICTION TREATMENT ASSOCIATION BOARD OF DIRECTORS. In the official journal, 9 (1), 2007.
  3. Wilens, T. E; Schubiner, H.; Downey, K. K; Arfken, C. L; Johanson, C-E.; Schuster, C. R; Lockhart, N.; Edwards, A.; Donlin, J.; Pihlgren, E.; Ziedonis, D. M; Rayford, B. S et al. Does Childhood Treatment of ADHD With Stimulant Medication. In Drug and alcohol dependence, 34 (1), 2007.

2006

  1. Auriacombe, M Are substitutes really part of therapy?. In Revue des Maladies Respiratoires, 23 (1 Suppl): 124-125, 2006.
  2. Fatseas, M; Lavie, E; Denis, C; Franques-Reneric, P; Tignol, J and Auriacombe, M Benzodiazepine withdrawal in subjects on opiate substitution treatment. In La Presse Médicale, 35 (4 Pt 1): 599-606, 2006.
  3. Tignol, J.; Martin-Guehl, C.; Aouizerate, B.; Grabot, D. and Auriacombe, M. Social phobia and premature ejaculation: a case–control study. In Depression and Anxiety, 23 (3): 153-157, 2006. doi 

2005

  1. Carret, N. Le; Auriacombe, S.; Letenneur, L.; Bergua, V.; Dartigues, J-F. and Fabrigoule, C. Influence of education on the pattern of cognitive deterioration in AD patients: The cognitive reserve hypothesis. In Brain and Cognition, 57 (2): 120-126, 2005. doi 
  2. Encrenaz, G; Rondeau, V; Messiah, A and Auriacombe, M Examining the influence of drop-outs in a follow-up of maintained opiate users. In Drug and Alcohol Dependence, 79 (3): 303-310, 2005. doi 
  3. Weinrieb, R. M; Auriacombe, M.; Lynch, K. G and Lewis, J. D Selective serotonin re-uptake inhibitors and the risk of bleeding. In Expert Opinion on Drug Safety, 4 (2): 337-344, 2005. doi 

2004

  1. Auriacombe, M.; Fatséas, M.; Dubernet, J.; Daulouède, J-P. and Tignol, J. French Field Experience with Buprenorphine. In American Journal on Addictions, 13 (s1): S17-S28, 2004. doi 
  2. Franques, P.; Auriacombe, M.; Lincheneau, P. M. and Tignol, J. Psychopathologie du sport. In EMC - Psychiatrie, 1 (1): 1-14, 2004. doi 

2003

  1. Aouizerate, B; Pujol, H; Grabot, D; Faytout, M; Suire, K; Braud, C; Auriacombe, M; Martín, D; Baudet, J and Tignol, J Body dysmorphic disorder in a sample of cosmetic surgery applicants. In European Psychiatry, 18 (7): 365-368, 2003. doi 
  2. Auriacombe, M; Fatseas, M; Franques-Reneric, P; Daulouede, J P and Tignol, J Substitution therapy in drug addictions. In La Revue du praticien, 53 (12): 1327-1334, 2003.
  3. Auriacombe, M.; Fatseas, M.; Franques-Rénéric, P.; Daulouède, J. P. and Tignol, J. Substitution treatments in addictions. In Revue du Praticien, 53 (12), 2003.
  4. Auriacombe, M.; Fatseas, M.; Franques-Rénéric, P.; Daulouède, J. P. and Tignol, J. Thérapeutiques de substitution dans les addictions. In Revue du Praticien, 53 (12), 2003.
  5. Cotto, E; Neau, D; Cransac-Neau, M; Auriacombe, M; Pellegrin, J.-L.; Ragnaud, J.-M.; Fillet, A.-M.; Belnard, M; Fleury, H and Lafon, M.-E. Borna Disease Virus RNA in Immunocompromised Patients in Southwestern France. In Journal of Clinical Microbiology, 41 (12): 5577-5581, 2003. doi 
  6. Mangon, E; Simon, S; Franques-Reneric, P and Auriacombe, M Development of diagnosis criteria for physical activity abuse and dependence: a qualitative study. In Annales de Medecine Interne, 154 (Spec N 2): 33-42, 2003.
  7. Mangon, E.; Simon, S.; Franques-Rénéric, P. and Auriacombe, M. Mise au point de critères diagnostiques pour l'abus et la dépendance à l'activité physique: Étude qualitative. In Annales de Medecine Interne, 154 (SPEC. ISS. 2), 2003.
  8. Poulet, E; Auriacombe, M and Tignol, J Seizure threshold and ECT. Importance for good clinical practice of ECT. A review of literature. In Encephale, 29 (2): 99-107, 2003.
  9. Weinrieb, R. M; Auriacombe, M.; Lynch, K. G; Chang, K-M. and Lewis, J. D A Critical Review of Selective Serotonin Reuptake Inhibitor–Associated Bleeding: Balancing the Risk of Treating Hepatitis C–Infected Patients. In The Journal of Clinical Psychiatry, 64 (12): 1502-1510, 2003. doi 

2002

  1. Amieva, H.; Lafont, S.; Auriacombe, S.; Carret, N. Le; Dartigues, J-F.; Orgogozo, J-M. and Fabrigoule, C. Inhibitory Breakdown and Dementia of the Alzheimer Type: A General Phenomenon?. In Journal of Clinical and Experimental Neuropsychology, 24 (4): 503-516, 2002. doi 
  2. Loustauneau, A; Auriacombe, M; Daulouede, J P and Tignol, J Is buprenorphine a potential alternative to methadone for treating pregnant drug users? Inventory of clinical data in the literature. In Annales de Medecine Interne, 153 (7 Suppl): 31-36, 2002.
  3. Loustauneau, A.; Auriacombe, M.; Daulouede, J. P. and Tignol, J. La buprénorphine est-elle une alternative potentielle à la méthadone pour le traitement de la femme enceinte toxicomane? Inventaire des données cliniques de la littérature. In Annales de Medecine Interne, 153 (7 SUPPL. 1), 2002.

2001

  1. Auriacombe, M. Deaths Attributable to Methadone vs Buprenorphine in France. In JAMA, 285 (1): 45, 2001. doi 
  2. Franques, P; Auriacombe, M and Tignol, J Sports, use of performance enhancing drugs and addiction. A conceptual and epidemiological review. In Annales de Medecine Interne, 152 Suppl (7): 37-49, 2001.
  3. Franques, P.; Auriacombe, M. and Tignol, J. Sport, dopage et addictons. Délimitations conceptuelles et approche épidémiologique à partir des données de la littérature. In Annales de Medecine Interne, 152 (7 SUPPL.), 2001.
  4. Gomez, F; Cantini, O; Valat, P; Usandizaga, D; Reynier, P; Janvier, G; Auriacombe, M and Tignol, J Anesthesia for electroconvulsive therapy. In Annales Françaises d Anesthésie et de Réanimation, 20 (2): 187-195, 2001.
  5. Mann, S C; Auriacombe, M; Macfadden, W; Caroff, S N; Cabrina Campbell, E and Tignol, J Lethal catatonia: clinical aspects and therapeutic intervention. A review of the literature. In L'Encéphale, 27 (3): 213-216, 2001.
  6. Mattick, R P; Ali, R; Auriacombe, M; Davoli, M; Faggiano, F; Farrell, M; Ferri, M and Ling, W Cochrane Drugs and Alcohol Group: the development of systematic reviews of treatment outcome. In Alcohol and Alcoholism, 36 (2): 109-111, 2001.
  7. Tignol, J; Martin, C; Auriacombe, M; Grabot, D; Pujol, H; de Grove, H; Gorse, F and Gouget, J F Case study–relationship between prevalence of shyness, social phobia and avoidant personality in male sexual disorders. In L'Encéphale, 27 (5): 418-422, 2001.

2000

  1. Auriacombe, M.; Poulet, E.; Daudet, C.; Glenisson, L.; Gomez, F.; Uzandisaga, D. and Tignol, J. L'électroconvulsivothérapie : Un traitement qui reste d'actualité. In Revue du Praticien - Medecine Generale, 14 (501), 2000.
  2. Auriacombe, M.; Rénéric, J-P.; Usandizaga, D.; Gomez, F.; Combourieu, I. and Tignol, J. Post-ECT Agitation and Plasma Lactate Concentrations. In The Journal of ECT, 16 (3): 263-267, 2000. doi 
  3. Bertorelle, V; Auriacombe, M; Grabot, D; Franques, P; Martin, C; Daulouede, J P and Tignol, J Quantitative evaluation of sharing practices of materials at risk for infectious virus contamination by intravenous opiate users seeking treatment–application of the RAB (Risk for AIDS Behavior) self-administered questionnaire. In Encephale, 26 (3): 3-7, 2000.
  4. Franques, P; Auriacombe, M and Tignol, J Addiction and personality. In L'Encéphale, 26 (1): 68-78, 2000.

1999

  1. Auriacombe, M; Afflelou, S; Lavignasse, P; Lafitte, C; Roux, D; Daulouede, J P and Tignol, J Pregnancy, abortion and delivery in a cohort of heroin dependent patients treated with drug substitution (methadone and buprenorphine) in Aquitaine. In La Presse Médicale, 28 (4): 177, 1999.
  2. Bonnand, B; Auriacombe, M; Franques, P; Bertorelle, V; Afflelou, S; Daulouede, J P; Combourieu, I and Tignol, J Evaluation of the use of psychotropic drugs from urine samples from subjects attending for the first time a clinic specializing in opium addiction. In La Presse Médicale, 28 (13): 679-682, 1999.

1998

  1. Amieva, H.; Lafont, S.; Auriacombe, S.; Rainville, C.; Orgogozo, J-M.; Dartigues, J-F. and Fabrigoule, C. Analysis of Error Types in the Trail Making Test Evidences an Inhibitory Deficit in Dementia of the Alzheimer Type. In Journal of Clinical and Experimental Neuropsychology, 20 (2): 280-285, 1998. doi 
  2. Glenisson, L; Auriacombe, M; Fernandez, T; Auriacombe, S; Gomez, F; Uzandisaga, D and Tignol, J Adverse seizure reactions after electroconvulsive therapy. Study of personal cases and review of the literature. In L'Encéphale, 24 (1): 1-8, 1998.

1997

  1. Afflelou, S; Auriacombe, M; Cazenave, M; Chartres, J P and Tignol, J Administration of high dose levothyroxine in treatment of rapid cycling bipolar disorders. Review of the literature and initial therapeutic application apropos of 6 cases. In L'Encéphale, 23 (3): 209-217, 1997.
  2. Auriacombe, M; Reneric, J P and Le Moal, M Animal models of anhedonia. In Psychopharmacology, 134 (4): 337-338, 1997. doi 

1996

  1. Auriacombe, M. Buprenorphine in the treatment of opiate addiction. European status. In European Psychiatry, 11: 234s, 1996. doi 
  2. Grabot, D; Martin, C; Auriacombe, M and Tignol, J Assisted evaluation scale of quality of life. In L'Encéphale, 22 (3): 181-185, 1996.
  3. Martin, C; Grabot, D; Auriacombe, M; Brisseau, S; Daulouede, J P and Tignol, J Descriptive studies of the use of the Addiction Severity Index in France. In L'Encéphale, 22 (5): 359-363, 1996.

1995

  1. Auriacombe, M; Grabot, D; Lincheneau, PM; Zeiter, D and Tignol, J Use of midazolam for ECT anesthesia: effects on antidepressive efficacy and seizure duration. Preliminary findings. In European Psychiatry, 10 (6): 312-316, 1995. doi 
  2. Auriacombe, M and Tignol, J Withdrawal and management of opiate addicts. In Rev Prat, 45 (11): 1383-1387, 1995.
  3. Benezech, M; Auriacombe, M; Martin, C and Serin, N The imperious need to create evaluation centers for criminologic expert assessment. In Ann Med Psychol (Paris), 153 (9): 597-600, 1995.

1994

  1. Auriacombe, M; O'Brien, C P and Tignol, J Buprenorphine in the treatment of opiate dependence. In Ann Med Interne (Paris), 145 Suppl (3): 27, 1994.
  2. Auriacombe, M and Tignol, J Electroshock therapy today. In La Revue du praticien, 44 (16): 2137-2139, 1994.
  3. Auriacombe, M.; Grabot, D.; Daulouède, J-P.; Vergnolle, J-P.; O'Brien, C. and Tignol, J. A naturalistic follow-up study of French-speaking opiate-maintained heroin-addicted patients: Effect on biopsychosocial status. In Journal of Substance Abuse Treatment, 11 (6): 565-568, 1994. doi 

1992

  1. Gariti, P.; Auriacombe, M.; Incmikoski, R.; McLellan, A.Thomas; Patterson, L.; Dhopesh, V.; Mezochow, J.; Patterson, M. and O'Brien, C. A randomized double-blind study of neuroelectric therapy in opiate and cocaine detoxification. In Journal of Substance Abuse, 4 (3): 299-308, 1992. doi 
  2. Woody, G. E. and Auriacombe, M. Drug abuse treatment. In Current Opinion in Psychiatry, 5 (3): 420-425, 1992. doi 

1991

  1. Auriacombe, M; Dhopesh, V and Yagnik, P Meralgia paresthetica syringectica. In JAMA, 265 (21): 2807-2808, 1991.
  2. Auriacombe, M and Tignol, J Electroconvulsive therapy and benzodiazepine: antagonism or indifference? Review of the literature. In L'Encéphale, 17 (6): 537-541, 1991.

1990

  1. Auriacombe, M.; Tignol, J.; Le Moal, M. and Stinus, L. Transcutaneous electrical stimulation with limoge current potentiates morphine analgesia and attenuates opiate abstinence syndrome. In Biological Psychiatry, 28 (8): 650-656, 1990. doi 
  2. Stinus, L.; Auriacombe, M.; Tignol, J.; Limoge, A. and Le Moal, M. Transcranial electrical stimulation with high frequency intermittent current (Limoge's) potentiates opiate-induced analgesia: blind studies. In Pain, 42 (3): 351-363, 1990. doi 
  3. Tignol, J; Plagnol, C; Auriacombe, M; Cazenave, M and O'Brien, C P Continuity in the neuroleptic treatment in patients with schizophrenia. Current data. In Annales Médico-psychologiques revue psychiatrique, 148 (3): 290-293, 1990.

Collections

2018

  1. Auriacombe, M.; Serre, F.; Denis, C. and Fatséas, M. Diagnosis of Addictions. In The Routledge Handbook of Philosophy and Science of Addiction, pages 132-144, Routledge, 1 [edition]. | New York : Routledge, 2018. | Series: Routledge handbooks in philosophy, 2018.

2015

  1. Fatseas, M.; Dubernet, J.; Daoulouède, J-P. and Auriacombe, M. Buprenorphine in the Treatment of Opioid Addiction: The French Experience. In Textbook of Addiction Treatment: International Perspectives, pages 501-510, Springer Milan, Milano, 2015.

2014

  1. Fatséas, M.; Denis, C. and Auriacombe, M. Chapitre 14. Héroïne et opiacés. In Addictions et comorbidités, pages 237-247, Dunod, 2014.

2013

  1. Denis, C.; Lavie, E.; Fatseas, M. and Auriacombe, M. Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings. In Cochrane Database of Systematic Reviews, John Wiley & Sons, Ltd, Chichester, UK, 2013.

2012

  1. Fatseas, M; Denis, C; Alexandre, J-M. and Auriacombe, M Les critères diagnostiques de la dépendance aux substances psycho-actives sont-ils valides pour le diagnostic du jeu pathologique ?. In Le jeu pathologique. Comprendre-Prévenir-Traiter, pages 101-105, Masson, Paris, Congrès de psychiatrie et de neurologie de langue française , 2012.

2007

  1. Auriacombe, M.; Notz, N. NN and Franques, P. PF Neuroelectric stimulation for the management of opioid withdrawal. In Cochrane Database of Systematic Reviews, John Wiley & Sons, Ltd, Chichester, UK, 2007.

2006

  1. Denis, C.; Fatseas, M.; Lavie, E. and Auriacombe, M. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. In Cochrane Database of Systematic Reviews, pages CD005194, John Wiley & Sons, Ltd, Chichester, UK, 2006.

In Proceedings

2013

  1. Fatseas, M; Serre, F; Swendsen, J and Auriacombe, M Does cue type matter for Craving?: Comparison of substance-specific and person-specific cues using mobile technologies. In 75th College on Problems of Drug Dependence, 2013.
  2. Serre, F; Fatseas, M; M., S J and Auriacombe, M Does craving predict substance use for different substance use disorders?: Ecological Momentary Assessment in alcohol, tobacco, cannabis and heroin dependence. In 75th College on Problems of Drug Dependence, 2013.
  3. Swendsen, J; Serre, F; Fatseas, M and Auriacombe, M A systematic review of studies exploring craving, its moderators, and the link with substance use in daily life using Ecological Momentary Assessment (EMA). In 75th College on Problems of Drug Dependence, 2013.

2012

  1. Fatseas, M; Serre, F; Swendsen, J and Auriacombe, M Relationships between sleep disturbances and variations of craving in patients beginning treatment for addiction: a computerized ambulatory monitoring study. In 74th College on Problems of Drug Dependence, Palm Springs, California, 2012.
  2. Quintin, J; Serre, F; Fatseas, M; Auriacombe, S and Auriacombe, M Relationships between decision making, type of addiction, and addiction severity. In 74th College on Problems of Drug Dependence, Palm Springs, California, 2012.
  3. Serre, F; Swendsen, J; Fatseas, M and Auriacombe, M Feasibility and validity of Ecological Momentary Assessment in alcohol, tobacco, cannabis and opiates dependent patients. In 74th College on Problems of Drug Dependence, Palm Springs, California, 2012.

2011

  1. Beltran, V; Aguerretxe Colina, A; Maitre, C; Auriacombe, M and Daulouède, J P Comorbidités psychiatriques chez les consommateurs de tabac. Etude transversale sur les consommateurs de tabac reçus au CSAPA BIZIA à Bayonne de 2006 à 2010. In 5èmes Journées de l'Albatros, Congrès international d'Addictologie, Paris, 2011.

2010

  1. Alexandre, J M; Humeau, M; Fatseas, M and Auriacombe, M Formation via Internet à la Psychothérapie : L'expérience en cours à l'Université Victor Segalen Bordeaux 2. In 11ème congrès IP3S, 2010.

2009

  1. Debrabant, R; Serre, F; Fatseas, M; Denis, C; Thoueilles, B; Fleury, B; Auriacombe, M; Fatséas, F; Denis, C; Thoueilles, P; Fleury, B and Auriacombe, M Pattern of alcohol use and associated factors: a cross-sectional study in a Franch emergency room. In 71st College on Problems of Drug Dependence, Reno, Nevada, 2009.

Misc

2014

  1. Auriacombe, M.; Denis, C. and Fatséas, M. Commentary on Scharkow etal. (2014): Welcomed and yet to come. Are we looking at what we are looking for?. doi 

 

 

 


Université de Bordeaux CNRS

CNRS UMR 6033



Participez à une étude...

A noter

Recrutement ARC


Directeur

Pr. Marc Auriacombe

Directeur adjoint

J. Taillard

Administration :

Tel : +33 (0)5 57 82 01 73

Bureau Recherche :

Tel : +33 (0)5 57 82 01 82

Adresse :

UMR 6033 SANPSY
CHU Pellegrin, Tripode
13ème étage, aile 3
Place Amélie- Raba-Léon
33076 Bordeaux cédex
France

logo SANPSY Accéder au laboratoire


Investissement d'Avenir Clinilabs Certified Site Clinilabs Certified Site